The White House has withdrawn Dr Heidi Overton’s nomination to lead the Food and Drug Administration, hours before the Senate health committee was due to vote on her confirmation. President Donald Trump nominated Overton, a physician and White House adviser, in August to succeed Marty Makary, who resigned as commissioner in May after a year in the job.
The White House said it pulled the nomination because Overton did not have the votes to be confirmed. But the Senate health committee’s chairman, Bill Cassidy of Louisiana, publicly disputed that account, saying he believed she would have cleared both his committee and the full Senate. “Tonight, the White House abandoned a viable confirmation path for Dr Overton,” Cassidy wrote on social media. “Unfortunately, with the limited time left, confirming a permanent FDA Commissioner will fall to Senate Democrats.”
Democrats flipped nine Senate seats in this month’s midterm elections and will hold a 56-44 majority when the new Congress is sworn in in January, meaning any permanent commissioner will now have to win Democratic support.
The final obstacle, according to Cassidy and other accounts, was a group of anti-abortion Republican senators who wanted firm commitments from the administration on the abortion pill mifepristone — including restoring the requirement that it be dispensed in person and completing the FDA’s safety review of the drug. Overton had told senators she would finish that review by March 2027, and Senator Josh Hawley of Missouri said he had been encouraged by her answers. But the White House withdrew her nomination rather than make the commitments the senators sought, Cassidy said.
The suddenness of the decision caught senior health officials by surprise, CNN reported, citing half a dozen people familiar with the matter. Some of Overton’s allies believe Health Secretary Robert F. Kennedy Jr. and the new White House chief of staff, Stephen Miller, had soured on her candidacy in the months since Trump first hailed her as a “rockstar” nominee. That account rests on unnamed sources and has not been confirmed by the White House.
The FDA will continue to be led on an interim basis by Kyle Diamantas, who stepped in after Makary’s departure. Reports suggest Republicans are considering Senator Roger Marshall of Kansas, who lost his seat in the midterms, as a possible replacement nominee — though that, too, remains unconfirmed.
Sources: Associated Press; CNN; Government Executive; Fox News.
